Trial of mGluR5 Antagonist AFQ056 in Patients with Fragile X
U.S. medical centers are recruiting men and women with Fragile X, ages 18-45, for a large-scale Phase IIb clinical trial. A trial involving children is planned to follow.
The randomized, double-blind, placebo-controlled clinical study sponsored by Novartis is designed to assess whether AFQ056 is safe and effective in treating the behavioral symptoms of Fragile X Syndrome. AFQ056 is an mGluR5 antagonist, which decreases mGluR5 activity in the brain. The trial involves 9 visits over 20 weeks, with many safety measures like blood draws and ECGs.
Detailed information is available at www.clinicaltrials.gov.
Trial of mGluR5 Antagonist AFQ056 in Patients with Fragile X
Tuesday, January 4, 20112comments
Labels:
clinical trial,
drug,
fragile X syndrome,
free,
medicine,
recrutiment
+ comments + 2 comments
his is really interesting, You are a very skilled blogger. I have joined your feed and look forward to seeking more of your excellent post.
www.gofastek.com
Thank you so much for writing it! i wish i could express my feelings far more eloquently.
www.n8fan.net
Post a Comment